Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
CJC-1295 with DAC
Limited
Research chemical
Summary
Long-acting GHRH analogue form of CJC-1295 using Drug Affinity Complex for multi-day GH/IGF-1 elevation research framing.
Categories
Growth Hormone Axis, Performance, Longevity
Mechanism
GHRH receptor agonism on pituitary somatotrophs with prolonged exposure from albumin binding, producing flatter multi-day GH/IGF-1 elevation than short pulses.
Half-life
Multi-day (DAC / albumin extension)
Routes
Subcutaneous injection
Legal / access
Not FDA-approved. Research powders are not pharmaceutical product.
Key risks
- Water retention
- Tingling / numbness
- IGF-1 elevation concerns
- Less physiologic GH pattern than pulse stacks
Common claims
- Fewer injections than no-DAC
- Sustained GH/IGF-1 support
- Recovery and lean-mass narratives
Select peptide B